$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000156459016023348 Filed on August 08, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$2.675B	$3.435B
YoY Change	-22.1%	8.26%
Cost Of Revenue	$2.671B	$2.446B
YoY Change	9.19%	8.88%
Gross Profit	$1.047B	$988.5M
YoY Change	5.88%	6.75%
Gross Profit Margin	39.12%	28.78%
Selling, General & Admin	$390.5M	$354.2M
YoY Change	10.25%	17.36%
% of Gross Profit	37.31%	35.83%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$180.3M	$158.8M
YoY Change	13.54%	8.84%
% of Gross Profit	17.23%	16.06%
Operating Expenses	$570.9M	$513.0M
YoY Change	11.29%	14.56%
Operating Profit	$431.1M	$480.5M
YoY Change	-10.28%	-0.77%
Interest Expense	-$103.4M	-$147.3M
YoY Change	-29.8%	-25.46%
% of Operating Profit	-23.98%	-30.65%
Other Income/Expense, Net	$3.215M	$2.311M
YoY Change	39.12%	36.5%
Pretax Income	$331.2M	$330.5M
YoY Change	0.21%	17.08%
Income Tax	$134.9M	$122.8M
% Of Pretax Income	40.72%	37.14%
Net Earnings	$53.38M	$170.5M
YoY Change	-68.69%	15.43%
Net Earnings / Revenue	2.0%	4.96%
Basic Earnings Per Share	$0.26	$0.80
Diluted Earnings Per Share	$0.26	$0.78
COMMON SHARES
Basic Shares Outstanding	204.5M shares	213.0M
Diluted Shares Outstanding	208.0M shares	217.6M

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.716B	$1.906B
YoY Change	-9.94%	28.32%
Cash & Equivalents	$1.283B	$933.7M
Short-Term Investments	$432.7M	$971.8M
Other Short-Term Assets	$187.8M	$189.5M
YoY Change	-0.93%	15.15%
Inventory	$197.4M	$159.4M
Prepaid Expenses
Receivables	$1.875B	$1.667B
Other Receivables	$558.1M	$456.5M
Total Short-Term Assets	$4.496B	$4.781B
YoY Change	-5.96%	14.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.972B	$2.565B
YoY Change	15.87%	11.97%
Goodwill
YoY Change
Intangibles	$1.631B
YoY Change
Long-Term Investments	$167.0M	$160.0M
YoY Change	4.38%	23.08%
Other Assets	$64.00M	$122.0M
YoY Change	-47.54%	84.55%
Total Long-Term Assets	$14.20B	$14.17B
YoY Change	0.21%	2.92%
TOTAL ASSETS
Total Short-Term Assets	$4.496B	$4.781B
Total Long-Term Assets	$14.20B	$14.17B
Total Assets	$18.69B	$18.95B
YoY Change	-1.35%	5.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$504.0M	$490.0M
YoY Change	2.86%	20.76%
Accrued Expenses	$807.0M	$679.0M
YoY Change	18.85%	8.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$144.0M	$109.0M
YoY Change	32.11%	-6.9%
Total Short-Term Liabilities	$2.646B	$2.334B
YoY Change	13.37%	-10.51%
LONG-TERM LIABILITIES
Long-Term Debt	$8.957B	$9.101B
YoY Change	-1.58%	8.46%
Other Long-Term Liabilities	$421.0M	$400.0M
YoY Change	5.25%	3.62%
Total Long-Term Liabilities	$9.378B	$9.501B
YoY Change	-1.29%	2361.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.646B	$2.334B
Total Long-Term Liabilities	$9.378B	$9.501B
Total Liabilities	$13.95B	$13.80B
YoY Change	1.06%	13.04%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$749.6M
YoY Change
Treasury Stock Shares	$10.43M
Shareholders Equity	$4.746B	$5.147B
YoY Change
Total Liabilities & Shareholders Equity	$18.69B	$18.95B
YoY Change	-1.35%	5.7%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	$53.38M	$170.5M
YoY Change	-68.69%	15.43%
Depreciation, Depletion And Amortization	$180.3M	$158.8M
YoY Change	13.54%	8.84%
Cash From Operating Activities	$516.6M	$31.40M
YoY Change	1545.22%	-88.03%
INVESTING ACTIVITIES
Capital Expenditures	$185.4M	$169.5M
YoY Change	9.44%	11.46%
Acquisitions
YoY Change
Other Investing Activities	-$18.50M	-$525.6M
YoY Change	-96.48%	452.68%
Cash From Investing Activities	-$203.9M	-$695.0M
YoY Change	-70.66%	181.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-70.50M	586.0M
YoY Change	-112.03%	96.18%
NET CHANGE
Cash From Operating Activities	516.6M	31.40M
Cash From Investing Activities	-203.9M	-695.0M
Cash From Financing Activities	-70.50M	586.0M
Net Change In Cash	242.2M	-77.60M
YoY Change	-412.11%	-124.71%
FREE CASH FLOW
Cash From Operating Activities	$516.6M	$31.40M
Capital Expenditures	$185.4M	$169.5M
Free Cash Flow	$331.2M	-$138.1M
YoY Change	-339.88%	-225.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	29791000
CY2016Q2	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	111428000
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	495000000
CY2016Q2	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	2459226000
	us-gaap	Costs And Expenses CostsAndExpenses	6306191000
CY2016Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3566000
CY2016Q2	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	897826000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	480548000
CY2016Q2	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	360599000
	us-gaap	Operating Income Loss OperatingIncomeLoss	693959000
	us-gaap	Operating Income Loss OperatingIncomeLoss	416392000
CY2016Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-505000
CY2016Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	176000000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4065000
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	201640000
CY2015Q2	dva	Debt Redemption Charge DebtRedemptionCharge	48072000
	dva	Debt Redemption Charge DebtRedemptionCharge	48072000
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2311000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6191000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	253000000
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	2954070000
CY2016Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	29791000
	us-gaap	Costs And Expenses CostsAndExpenses	6604828000
CY2015Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	104248000
CY2015Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4065000
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	205778000
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-99000
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	16000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	330539000
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	122762000
CY2015Q2	us-gaap	Profit Loss ProfitLoss	207777000
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	37300000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	170477000
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	217606198
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-2453000
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-789000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	274926000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	84113000
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	94153000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1778000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	494372000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	168458000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	261710000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36829000
	us-gaap	Profit Loss ProfitLoss	232662000
	us-gaap	Profit Loss ProfitLoss	131629000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	81846000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	71769000
	us-gaap	Net Income Loss NetIncomeLoss	150816000
	us-gaap	Net Income Loss NetIncomeLoss	59860000
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	212991606
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204432315
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	213188268
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207987530
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	217790617
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-8085000
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-8213000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-913000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-1601000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	867000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	283000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	93000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	173000
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5025000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6337000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-12860000
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1283416000
CY2016Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	394166000
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1875403000
CY2016Q2	us-gaap	Inventory Net InventoryNet	197388000
CY2016Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	558081000
CY2016Q2	us-gaap	Other Assets Current OtherAssetsCurrent	187763000
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	60070000
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1631001000
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1687326000
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3246000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-61000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19362000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	211023000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	232601000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	112267000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	37300000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	81995000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	71769000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	173723000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	150606000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	40498000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1499116000
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	408084000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1724228000
CY2015Q4	us-gaap	Inventory Net InventoryNet	185575000
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	435885000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	190322000
CY2016Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	48682000
CY2016Q2	us-gaap	Treasury Stock Value TreasuryStockValue	749598000
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60036000
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	4746054000
CY2016Q2	us-gaap	Minority Interest MinorityInterest	212649000
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4958703000
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18691630000
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	279429000
CY2016Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	2622476000
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	852860000
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	217338629
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	40920000
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	206904375
CY2016Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	10434254
	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	-493775000
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	349736000
	us-gaap	Share Based Compensation ShareBasedCompensation	23717000
	dva	Employee Service Stock Based Compensation Tax Benefit From Compensation Expense EmployeeServiceStockBasedCompensationTaxBenefitFromCompensationExpense	23658000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	10604000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	19952000
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-14275000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	23120000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	104005000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9213000
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	107610000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	431000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	121972000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-31531000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	945639000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	7873000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	518965000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	5337000
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	545685000
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	8785000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-947337000
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contingencies</p></td></tr></table></div> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</p> <p style="margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inquiries by the Federal Government and Certain Related Civil Proceedings</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vainer Private Civil Suit</font>: As previously disclosed, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters, covering the period from January 2003 to December 2008. The Company subsequently learned that the allegations underlying this inquiry were made as part of a civil complaint filed by relators, Daniel Barbir and Dr. Alon Vainer, pursuant to the qui tam provisions of the federal False Claims Act (FCA). The relators also alleged that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of $450,000 and attorney fees and other costs of $45,000 which was paid in 2015.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2011 U.S. Attorney Medicaid Investigation</font>: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request related to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company’s understanding that this inquiry is civil in nature. The Company understands further that certain other providers that operate dialysis clinics in New York may have received a similar request for documents. The Company cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle with the government. In March 2016, the Company finalized and executed settlement agreements with the State of New York and the U.S. Department of Justice (DOJ), including a settlement payment of an immaterial amount.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Swoben Private Civil Suit</font>: In April 2013, the Company’s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal FCA and the California False Claims Act, James M. Swoben, as relator, filed a <font style="font-style:italic;">qui tam</font> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a Settlement Agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal FCA and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services (CMS). In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Attorney Transportation Investigation</font>: In February 2015, the Company announced that it received six administrative subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena seeks the medical records of a single patient of each respective dialysis center. In February 2016, the Company received four additional subpoenas for four additional dialysis centers in southern California. The subpoenas were similarly limited in scope to the subpoenas received in 2015. The Company has been advised by an attorney with the United States Attorney’s Office for the Central District of California that the subpoenas relate to an investigation concerning the medical necessity of patient transportation. The Company does not provide transportation nor does it bill for the transport of its dialysis patients. The Company does not know the scope of the investigation by the government, nor what conduct or activities might be the subject of the investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. OIG Medicare Advantage Civil Investigation</font>: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of HCP, received a subpoena from the OIG. The Company has been advised by an attorney with the Civil Division of the United States Department of Justice in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning Medicare Advantage service providers’ risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain Medicare Advantage plans for which JSA provided services. It also requests information regarding JSA’s communications about patient diagnoses as they relate to certain Medicare Advantage plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government’s investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company’s and its subsidiaries’ (including HCP’s and its subsidiary JSA’s) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. The information requested includes information relating to patient diagnosis coding practices for a number of conditions, including potentially improper historical HCP coding for a particular condition. With respect to that condition, the guidance related to that coding issue was discontinued following the Company’s November 1, 2012 acquisition of HCP, and the Company notified CMS in April 2015 of the coding practice and potential overpayments. The Company is cooperating with the government and is producing the requested information. In addition, the Company is continuing to review other HCP coding practices to determine whether there were any improper coding issues. In that regard, the Company has identified certain additional coding practices which may have been problematic and is in discussions with the DOJ about the scope and nature of a review of claims relating to those practices. In connection with the HCP merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company has submitted an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred relating to these matters and intends to pursue recovery from the escrow. However, the Company can make no assurances that the indemnification and escrow will cover the full amount of the Company’s potential losses related to these matters. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Department of Justice Vascular Access Investigation and Related Qui Tam Litigation</font>: In November 2015, the Company announced that RMS Lifeline, Inc., a wholly-owned subsidiary of the Company that operates under the name Lifeline Vascular Access (Lifeline), received a Civil Investigative Demand (CID) from the DOJ. The CID relates to two vascular access centers in Florida that are part of Lifeline’s vascular access business. The CID covers the period from January 1, 2008 through the present. The Company acquired these two centers in December 2012. Based on the language of the CID, the DOJ appeared to be looking at whether angiograms performed at the two centers were medically unnecessary and therefore whether related claims filed with federal healthcare programs possibly violated the FCA. Lifeline does not perform dialysis services but instead provides <font style="Background-color:#FFFFFF;">vascular access management services for dialysis patients</font>. The Company cooperated with the government and produced requested information. The DOJ investigation was initiated pursuant to a complaint brought under the qui tam provisions of the FCA (the Complaint). The Complaint was originally filed under seal in August 2014 in the U.S. District Court, Middle District of Florida, United States ex. rel James Spafford v. DaVita HealthCare Partners, Inc., et al., Case Number 6:14-cv-1251-Orl-41DAB. In December 2015, a First Amended Complaint was filed under seal. In May 2016, the First Amended Complaint was unsealed. The First Amended Complaint alleges violations of the FCA due to the submission of claims to the government for allegedly medically unnecessary angiograms and angiography procedures at the two vascular access centers. The Complaint covers alleged conduct dating from July 2008, prior to the Company’s acquisition of the centers, to the present. The DOJ has declined to intervene.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2016 U.S. Attorney Prescription Drug Investigation</font>: In early February 2016, the Company announced that its pharmacy services wholly-owned subsidiary, DaVita Rx, received a CID from the U.S. Attorney’s Office for the Northern District of Texas. Based on the language of the CID, it appears the government is conducting an FCA investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications. The CID covers the period from January 1, 2006 through the present. In the spring of 2015, the Company initiated an internal compliance review of DaVita Rx during which it identified potential billing and operational issues. The Company notified the government in September 2015 that it was conducting this review of DaVita Rx and began providing regular updates of its review. In the fourth quarter of 2015, the Company recorded an estimated accrual of $22,530 for potential damages and liabilities associated with write-offs and discounts of patient co-payment obligations, and credits to payors for returns of prescriptions drugs, related to DaVita Rx that were identified during the course of this internal compliance review. Upon completion of its review, the Company filed a self-disclosure with the OIG in early February 2016 and has been working to address and update the practices it identified in the self-disclosure, some of which overlap with information requested by the U.S. Attorney’s Office. The Company may accrue additional reserves for refunds and related damages and potential liabilities arising out of this review. The Company does not know if the U.S. Attorney’s Office, which is part of the DOJ, knew when it served the CID on the Company that it was already in the process of developing a self-disclosure to the OIG. The OIG informed the Company in late February that its submission was not accepted. They indicated that the OIG is not expressing an opinion regarding the conduct disclosed or the Company’s legal positions. The Company is cooperating with the government and is producing the requested information.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Solari Post-Acquisition Matter</font>:<font style="font-style:italic;"> </font>In 2016, HCP Nevada disclosed to the <font style="color:#000000;">OIG for HHS that </font>proper procedures for clinical and eligibility determinations may not have been followed by Las Vegas Solari Hospice (Solari), which was acquired by HCP Nevada in March 2013. In June 2016, the Company was notified by the OIG the disclosure submission had been accepted into the OIG’s Self Disclosure Protocol. The Company recorded an estimated accrual of $<font style="color:#000000;">16,000 </font>for potential damages and liabilities associated with this matter. HCP Nevada had previously made a disclosure and repayment of overpayments to National Government Services (NGS), the Medicare Administrative Contractor for HCP Nevada, for claims submitted by Solari to the federal government prior to HCP’s acquisition of Solari and claims made to the government post-acquisition for which the sellers had certain responsibilities pursuant to a management services agreement. The Company may accrue additional reserves for potential damages and liabilities related to this matter. The Company is cooperating with the government in this matter.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. In addition to the inquiries and proceedings specifically identified above, the Company is frequently subject to other inquiries by state or federal government agencies and/or private civil qui tam complaints filed by relators. Responding to subpoenas or government inquiries and defending the Company in relator proceedings has required and will continue to require management’s attention and significant legal expense. Any negative findings in any government inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and if criminal proceedings were initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.</p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shareholder Derivative Claims </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DaVita HealthCare Partners Inc. Derivative Litigation</font>: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that the Company’s directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney physician relationship investigations, the Vainer qui tam private civil suit described above and the Woodard qui tam private civil suit for which the Company previously announced a settlement in July 2012. The Company entered into a settlement with the lead plaintiff, which settlement (as previously disclosed), was described in a court-ordered notice sent to shareholders in late January 2015, and included enhancements to the Company’s corporate governance practices and provided that the Company will not oppose the derivative plaintiff’s application for an award of fees and expenses, the dollar amount of which is not material to the Company. The Court approved the settlement and entered an order granting final approval of the settlement on June 5, 2015 and final judgment in the case was entered on June 9, 2015. </p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the DOJ and certain agencies of the U.S. government. The Company has not received any further indication that any of these claims are active, except for one payor claim relating to a special needs plan, and some of the other claims may be barred by applicable statutes of limitations. The Company is working to resolve the one active claim of which it is aware and, based on the dollar amount of the claim, expects that its eventual resolution will involve an amount that is immaterial.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.</p></div>
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	7550000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	28144986000
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	27476994000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	58539000
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	79040000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9465000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4680000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	10604000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	16913000
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	13117000
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	18040000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	10840000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	475093000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-793000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-31506000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	933735000
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">New accounting standards</p></td></tr></table></div> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Update (ASU) No. 2015-02, <font style="font-style:italic;">Consolidation (Topic 810): Amendments to the Consolidation Analysis </font>as of January 1, 2016. The amendments in this ASU modify, simplify and expand certain aspects of consolidation guidance, principally with respect to limited partnerships, service fee arrangements and related parties. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASU No. 2015-05, <font style="font-style:italic;">Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement</font>, which amends ASC 350-40<font style="font-style:italic;">, Intangibles-Goodwill and Other-Internal-Use Software</font> as of January 1, 2016. The provisions of this statement were applied prospectively. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If an arrangement includes a software license, the accounting for the license will be consistent with licenses of other intangible assets. If the arrangement does not include a license, the arrangement will be accounted for as a service contract. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASU No. 2015-16, <font style="font-style:italic;">Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments </font>as of January 1, 2016<font style="font-style:italic;">. </font>The amendments in this ASU allow an acquirer to recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This will be inclusive of the effect on earnings of changes in depreciation, amortization, or other income effects as a result of the change to provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in this ASU were applied prospectively. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instrument – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.</font> The amendment will replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable supporting information to inform credit loss estimates. The amendments in this ASU are effective for the Company beginning January 1, 2020 and early adoption is permitted only as of January 1, 2019. The Company has not yet determined what the effects of adopting this ASU will be on its consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-09, <font style="font-style:italic;">Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font>, as part of its Simplification Initiative. The areas for simplification in this ASU involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this ASU are effective for the Company beginning January 1, 2017 and early adoption is permitted. The method of adoption differs for each of the topics covered by the ASU. The Company has not yet determined what the effects of adopting this ASU will be on its consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-07, <font style="font-style:italic;">Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. </font>The amendments in this ASU eliminate the requirement that when an investment qualifies for the use of equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this ASU are effective for the Company beginning on January 1, 2017 and should be applied prospectively. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, <font style="font-style:italic;">Leases (Topic 842)</font>. The amendments in this ASU revise the accounting related to lessee accounting. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for substantially all leases with lease terms in excess of twelve months. The new lease guidance also simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. The amendments in this ASU are effective for the Company beginning on January 1, 2019 and should be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. The Company has assembled an internal lease task force that meets regularly to discuss and evaluate the overall impact of this guidance on the consolidated financial statements and related disclosures, as well as the expected timing and method of adoption. The Company believes that the new standard will have a material impact on its consolidated balance sheet but it will not have a material impact on its liquidity. The Company continues to evaluate the effect that the implementation of this standard will have on its consolidated financial statements and related disclosures. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the FASB issued ASU No. 2016-01, <font style="font-style:italic;">Financial Statements – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. </font>The amendments in this ASU revise the accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities at fair value. The amendments in this ASU are effective for the Company beginning on January 1, 2018 and should be applied through a cumulative-effect adjustment to the statement of financial position. Early adoption is permitted under certain circumstances. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the FASB issued ASU No. 2015-11, <font style="font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory. </font>The amendments in this ASU apply to all inventory with the exception of inventory measured using last-in, first-out or the retail inventory method. This ASU simplifies the measurement of inventory. Under this new standard, inventory should be measured using the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonable predictable costs of completion, disposal and transportation. The amendments in this ASU are effective for the Company beginning January 1, 2017 and should be applied prospectively. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In July 2015, the FASB issued ASU 2015-14, <font style="font-style:italic;">Revenue from Contracts with Customers</font> <font style="font-style:italic;">(Topic </font>606): Deferral of Effective Date. This guidance approves a one-year deferral of the effective date of ASU 2014-09. The ASU now permits the Company to adopt this standard on January 1, 2018. Early application is permitted as of the initial effective date of January 1, 2017, but not prior to that date. In March, April and May 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12, <font style="font-style:italic;">Revenue from Contracts with Customers</font> <font style="font-style:italic;">(Topic 606)</font>, which amends the guidance in ASU 2014-09. The Company has assembled an internal revenue task force that meets regularly to discuss and evaluate the overall impact this guidance will have on various revenue streams in the consolidated financial statements and related disclosures, as well as the expected timing and method of adoption. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</p></div>
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	691000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2042000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1046000
CY2016Q2	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1.00
	dva	Accounts Receivable Period Outstanding AccountsReceivablePeriodOutstanding	P3M
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	15285000
CY2016Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	382664000
CY2016Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	50056000
CY2016Q2	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	206692000
CY2015Q2	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	215186000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	206626000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	215382000
CY2016Q2	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
CY2015Q2	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1355000
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2420000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1362000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2409000
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1811000
CY2015Q2	dva	Debt Redemption And Refinancing Charges DebtRedemptionAndRefinancingCharges	48072000
CY2016Q2	us-gaap	Marketable Securities MarketableSecurities	432720000
CY2015Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	406884000
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	33482000
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	440366000
CY2016Q2	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	382664000
CY2016Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	11502000
CY2015Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	406884000
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1200000
CY2016Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	38554000
CY2016Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	38554000
CY2015Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	32282000
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	32282000
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	3561000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	2589000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	1347000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	385000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	152000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	284000
	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	93000
	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	173000
CY2014Q4	us-gaap	Goodwill Goodwill	9415295000
CY2015	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	97093000
CY2015	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	8781000
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	192834000
CY2015	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-16294000
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	321012000
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	4980000
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	3446000
	us-gaap	Goodwill Impaired Facts And Circumstances Leading To Impairment GoodwillImpairedFactsAndCircumstancesLeadingToImpairment	Based on continuing developments at the Company’s HCP reporting units during the second quarter of 2016, including the Medicare Advantage final benchmark rates for 2017 announced on April 4, 2016, further changes in expectations concerning future government reimbursement rates and the Company’s expected ability to mitigate them, as well as medical cost and utilization trends, underperformance of certain at-risk units in recent quarters and other market conditions, the Company performed additional impairment assessments for certain at-risk HCP reporting units during the quarter ended June 30, 2016.
	us-gaap	Goodwill Impaired Change In Estimate Description GoodwillImpairedChangeInEstimateDescription	For example, a sustained, long-term reduction of 3% in operating income for HCP Nevada or HCP Florida could reduce their estimated fair values by up to 2.2% and 1.6%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP Nevada and HCP Florida by up to 4.8% and 4.5%, respectively.
	dva	Increase Decrease In Prior Year Estimates Of Health Care Costs Payable IncreaseDecreaseInPriorYearEstimatesOfHealthCareCostsPayable	6424000
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	42915000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	39011000
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	3904000
CY2016Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10560000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	9918000
CY2016Q2	us-gaap	Senior Notes SeniorNotes	4500000000
CY2015Q4	us-gaap	Senior Notes SeniorNotes	4500000000
CY2016Q2	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	71515000
CY2015Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	70645000
CY2016Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	287838000
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	283185000
CY2016Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9189353000
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9226330000
CY2016Q2	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	87913000
CY2015Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	95985000
CY2016Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9101440000
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9130345000
	dva	Debt Redemption And Refinancing Charges DebtRedemptionAndRefinancingCharges	48072000
CY2016Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	185440000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	64897000
CY2016Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.28
CY2015Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.81
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.77
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	76295000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	153660000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	169716000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	742290000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	66640000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3298210000
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	4682542000
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0442
CY2016Q2	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0443
	us-gaap	Unrecorded Unconditional Purchase Obligation Description UnrecordedUnconditionalPurchaseObligationDescription	Certain consolidated joint ventures are originally contractually scheduled to dissolve after terms ranging from ten to fifty years.
	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	50647000
	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	69692000
	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	8160000
	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	10028000
CY2016Q2	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet	139505000
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	70835000
	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition	P1Y1M6D
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	23658000
	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	28040000
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	3690000
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	249481000
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	67.61
CY2015Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	259252000
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P8Y
CY2016Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	72190000
CY2016Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3709756000
CY2015Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3530347000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	7346872000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	6918308000
CY2016Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	56969000
CY2015Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	172551000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	156753000
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.30
CY2016Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.27
CY2015Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.79
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.75
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.30
CY2015Q4	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	34135000
	dva	Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss	3304000
	dva	Business Combination Contingent Consideration Acquisitions Earnouts Payments BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments	11197000
CY2016Q2	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	19634000
CY2016Q2	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	642518000
CY2016Q2	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	390477000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2016Q2	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	5417000
CY2015Q2	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	3425000
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	12337000
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	9558000
	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	205778000
	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	473314000
CY2015Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169452000
CY2016Q2	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	-2078000
CY2015Q2	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	-8421000
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	-4530000
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	-8421000
CY2016Q2	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	51304000
CY2015Q2	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	162056000
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	146286000
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	51439000
CY2015Q2	dva	Debt Expense Including Debt Redemption Charges DebtExpenseIncludingDebtRedemptionCharges	152320000
	dva	Debt Expense Including Debt Redemption Charges DebtExpenseIncludingDebtRedemptionCharges	249712000
CY2016Q2	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1337398000
CY2016Q2	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	231048000
CY2016Q2	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10150362000
CY2015Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1279936000
CY2015Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	241050000
CY2015Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10167499000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	712977000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-56319000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-61233000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-342321000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	309902000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	614820000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	667992000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-192899000

Files In Submission

Name	View Source	Status
0001564590-16-023348-index-headers.html	Edgar Link	pending
0001564590-16-023348-index.html	Edgar Link	pending
0001564590-16-023348.txt	Edgar Link	pending
0001564590-16-023348-xbrl.zip	Edgar Link	pending
dva-10q_20160630.htm	Edgar Link	pending
dva-20160630.xml	Edgar Link	completed
dva-20160630.xsd	Edgar Link	pending
dva-20160630_cal.xml	Edgar Link	unprocessable
dva-20160630_def.xml	Edgar Link	unprocessable
dva-20160630_lab.xml	Edgar Link	unprocessable
dva-20160630_pre.xml	Edgar Link	unprocessable
dva-ex121_7.htm	Edgar Link	pending
dva-ex311_10.htm	Edgar Link	pending
dva-ex312_9.htm	Edgar Link	pending
dva-ex31_804.htm	Edgar Link	pending
dva-ex321_8.htm	Edgar Link	pending
dva-ex322_6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2016 Q2 Form 10-Q Financial Statement

#000156459016023348 Filed on August 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2016 Q2 Form 10-Q Financial Statement

#000156459016023348 Filed on August 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva